Fig. 6From: Can roflumilast, a phosphodiesterase-4 inhibitor, improve clinical outcomes in patients with moderate-to-severe chronic obstructive pulmonary disease? A meta-analysisEffects of roflumilast vs. placebo on post-bronchodilator FVC, FEV6 and FEF25-75. CI, confidence interval; FEF25-75, forced expiratory flow between 25 and 75 % of the vital capacity; FEV6, force expiratory volume in six seconds; FVC, forced vital capacity; SD, standard derivationBack to article page